144 related articles for article (PubMed ID: 21631342)
1. Cytarabine dose for acute myeloid leukemia.
Mori J; Tsubokura M; Kami M
N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
[No Abstract] [Full Text] [Related]
2. Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
Wiernik A; Sperr WR; Weisdorf D; Valent P; Ustun C
Am J Hematol; 2013 Jun; 88(6):533-4. PubMed ID: 23526441
[No Abstract] [Full Text] [Related]
3. Cytarabine dose for acute myeloid leukemia.
Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
[TBL] [Abstract][Full Text] [Related]
4. Cytarabine dose for acute myeloid leukemia.
Mathisen MS
N Engl J Med; 2011 Jun; 364(22):2167; author reply 2168-9. PubMed ID: 21631341
[No Abstract] [Full Text] [Related]
5. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
Löwenberg B
Blood; 2013 Jan; 121(1):26-8. PubMed ID: 23287624
[TBL] [Abstract][Full Text] [Related]
6. Isolated Bilateral Ear and Scalp Rash After Cytarabine Therapy for Acute Myelogenous Leukemia: A Report and Literature Review.
Waseem H; Henriquez Felipe C; Hashmi AT; Ansar M; Batool A; Saverimuthu A; Kamholz SL
Am J Ther; 2019; 26(5):e653-e655. PubMed ID: 30418222
[No Abstract] [Full Text] [Related]
7. Evidence for sinoatrial blockade associated with high dose cytarabine therapy.
Stamatopoulos K; Kanellopoulou G; Vaiopoulos G; Stamatellos G; Yataganas X
Leuk Res; 1998 Aug; 22(8):759-61. PubMed ID: 9680105
[TBL] [Abstract][Full Text] [Related]
8. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
[No Abstract] [Full Text] [Related]
9. Anterior uveitis associated with high-dose cytosine arabinoside.
Fintelmann RE; Qian Y; Skalet A; Jeng BH
Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
[TBL] [Abstract][Full Text] [Related]
10. Severe anterior uveitis as a complication of high-dose cytosine-arabinoside.
Moberg J; Carlsson M; Holm C; Koranyi G
Acta Ophthalmol; 2009 Nov; 87(8):922-3. PubMed ID: 19799589
[No Abstract] [Full Text] [Related]
11. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
[TBL] [Abstract][Full Text] [Related]
12. "Flushing out" cytosine arabinoside from CSF to reverse neurotoxicity.
Bleyer A
J Pediatr Hematol Oncol; 2007 Apr; 29(4):274. PubMed ID: 17414574
[No Abstract] [Full Text] [Related]
13. [Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
Horikoshi Y; Kobayashi R; Endo M; Watanabe A; Kikuta A; Koike K; Hanada R; Hosoya R; Ohara A; Ikuta K; Goto H; Asami K; Sugita K; Horibe K; Tsurusawa M; Hori T; Hara J; Nishimura S; Nagatoshi Y; Mugishima H; Ohta S; Adachi S; Tsukimoto I
Rinsho Ketsueki; 2010 Feb; 51(2):104-13. PubMed ID: 20379101
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Deisseroth A; Farrell A; Justice R; Kane R; Sridhara R; Chen H; He K; Pazdur R
Blood; 2010 Jan; 115(2):430. PubMed ID: 20075171
[No Abstract] [Full Text] [Related]
15. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
17. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
[No Abstract] [Full Text] [Related]
18. Two cases of cytarabine syndrome successfully resolved by desensitization.
Lim KH; Kim JY; Kang MG; Park HK; Kang HR
J Investig Allergol Clin Immunol; 2015; 25(1):80-2. PubMed ID: 25898709
[No Abstract] [Full Text] [Related]
19. Control of acute myeloid leukemia morbidity in northwest Iran.
Eivazi-Ziaei J
Asian Pac J Cancer Prev; 2005; 6(4):472-3. PubMed ID: 16435994
[TBL] [Abstract][Full Text] [Related]
20. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
[No Abstract] [Full Text] [Related]
[Next] [New Search]
